BioStock at NLSDays: Stayble steps up partnering activities

Stayble’s most important milestones going forward are to present study results from the phase IIb study with the drug candidate STA363 and then enter into a license agreement with a larger player for phase III. Thus, the company will put more focus on partnering activities during the autumn and 2023. An important part of this work is to participate in partnering events, such as Nordic Life Science Days 2022 in Malmö where BioStock got the chance to interview CEO Andreas Gerward.

Read the article and watch the interview at biostock.se:

https://www.biostock.se/en/2022/10/nlsdays-stayble-steps-up-partnering-activities/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se